Long-term follow-up of TScan TCR-T therapies
Official title: A Long-term Follow-up Study to Assess Safety in Participants Who Received an Investigational T-Cell Receptor Engineered T-Cell (TCR-T) Product
Run by TScan Therapeutics, Inc. · NCT06976736 · Data updated 2026-11-12
This follow-up will see if the TSC-100 and TSC-101 TCR-T therapies remain safe and continue to control disease over the long term in people who already received them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 110 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | TScan Therapeutics, Inc. Industry-sponsored |
| Locations | 2 sites (Duarte, California and 1 other locations) |
| Status | Recruiting |
| Started | September 9, 2025 |
| Main results expected | September 2040 |
| Study ends | September 2040 |
| Registry record updated | September 10, 2025 |
| Trial ID | NCT06976736 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people who previously received a TSC-100 or TSC-101 TCR-T product in a TScan-sponsored trial and can provide informed consent for long-term follow-up.
✕Probably not a fit
Patients who did not previously receive TSC-100 or TSC-101 or who are seeking a new investigational therapy are unlikely to receive direct treatment benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants who previously received TSC-100 or TSC-101 in the TSCAN-001 protocol will be enrolled for long-term monitoring without receiving additional study drug. The study is observational and will collect safety and disease outcome data for 15 years from the date of original TCR-T administration. Participants may receive other clinically indicated cancer treatments while being followed. Routine visits and data collection will track late adverse events, durability of response, and survival outcomes.
Why it matters
Potential benefit: If successful, the follow-up could show whether these TCR-T therapies have durable safety and long-lasting disease control, helping guide future patient care.
How similar studies have gone: Long-term follow-ups of other cellular therapies like CAR-T have provided valuable safety and durability data, but published long-term data specific to TScan's TCR-T products are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants who received a TCR-T cellular therapy in a clinical study sponsored by TScan Therapeutics. * Signed informed consent. Exclusion Criteria: * None
Where it's running
-
City of Hope
Duarte, California, United States Recruiting -
Mount Sinai
New York, New York, United States Recruiting
Study contacts
- Study coordinator: Madhavi Desai
- Email: medicalaffairs@tscan.com
- Phone: (857) 399-9832
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS
This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.
-
CG009301 for adults with relapsed or treatment‑resistant blood cancers
This trial will try a new drug called CG009301 to see if it's safe and helps adults whose leukemia or related blood cancers have come back or not responded to prior treatment.
-
Using genetic information to guide maintenance therapy after stem cell transplantation for blood cancers
This study is testing whether personalized treatment based on genetic information can help people with blood cancers like acute myeloid leukemia and myelodysplastic syndromes stay healthy after a stem cell transplant.
-
Ivosidenib maintenance after allogeneic stem cell transplant for IDH1‑mutant AML or high‑risk MDS
This will test whether taking ivosidenib after a recent allogeneic stem cell transplant helps people with AML or high‑risk MDS who have an IDH1 mutation stay in remission longer.
-
Combination therapy with Venetoclax and Decitabine for relapsed or refractory AML
This study is testing a new combination treatment of Venetoclax and Decitabine to see if it can help people with newly diagnosed or returning acute myeloid leukemia feel better and achieve remission.
-
Using Tagraxofusp to treat pediatric patients with relapsed or refractory blood cancers
This study is testing a new drug called Tagraxofusp to see if it can help children and young adults with tough-to-treat blood cancers feel better and improve their chances of recovery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.